Latest news with #FreeStyleLibre
Yahoo
20-07-2025
- Business
- Yahoo
How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts
Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, it has earned the trust of both doctors and consumers, making its well-established brands more appealing in the market. In recent years, Abbott Laboratories (NYSE:ABT)'s diabetes care division has emerged as its strongest growth engine, thanks largely to its continuous glucose monitoring (CGM) product line, FreeStyle Libre. According to the company, FreeStyle Libre has achieved record-breaking dollar sales, making it the most successful medical device in history. Despite this milestone, significant room for growth remains, as a large number of diabetics worldwide have yet to adopt CGM technology, despite its clear benefits. In addition, Abbott Laboratories (NYSE:ABT) holds the status of a Dividend King with 53 consecutive years of dividend growth under its belt. The company has grown its dividend payouts by nearly 146% over the past ten years. With a business model designed for durability, the company is seen as a reliable option for investors seeking steady dividend growth in the years ahead. It currently offers a quarterly dividend of $0.59 per share and has a dividend yield of 1.95%, as of July 17. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-07-2025
- Business
- Yahoo
How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts
Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, it has earned the trust of both doctors and consumers, making its well-established brands more appealing in the market. In recent years, Abbott Laboratories (NYSE:ABT)'s diabetes care division has emerged as its strongest growth engine, thanks largely to its continuous glucose monitoring (CGM) product line, FreeStyle Libre. According to the company, FreeStyle Libre has achieved record-breaking dollar sales, making it the most successful medical device in history. Despite this milestone, significant room for growth remains, as a large number of diabetics worldwide have yet to adopt CGM technology, despite its clear benefits. In addition, Abbott Laboratories (NYSE:ABT) holds the status of a Dividend King with 53 consecutive years of dividend growth under its belt. The company has grown its dividend payouts by nearly 146% over the past ten years. With a business model designed for durability, the company is seen as a reliable option for investors seeking steady dividend growth in the years ahead. It currently offers a quarterly dividend of $0.59 per share and has a dividend yield of 1.95%, as of July 17. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
17-07-2025
- Business
- Yahoo
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
Abbott Laboratories ABT reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks Consensus Estimate by 0.8%. The figure improved 10.5% from the prior-year quarter's level. GAAP EPS was $1.01 compared with 74 cents in the second quarter of 2024. Following the earnings announcement, ABT stock fell 5% at pre-market trading today. The share price drop might be due to its reserved third-quarter guidance, which came in slightly below the Zacks Consensus Estimate. ABT's Q2 Revenues Worldwide sales of $11.14 billion were up 7.4% year over year on a reported basis. The top line surpassed the Zacks Consensus Estimate by 0.6%. Organically, sales improved 6.9% year over year. Organic sales, ex-COVID rose 7.5% year over year. ABT's Q2 Results in Detail Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics. Established Pharmaceuticals' product sales increased 6.9% on a reported basis (7.7% on an organic basis) to $1.38 billion. Organic sales in key emerging markets improved 8.7% year over year. This was led by double-digit growth in several countries, including Asia, Latin America and the Middle East. In the second quarter, the Medical Devices segment's sales rose 13.4% year over year on a reported basis (12.2% organically) to $5.37 billion. Sales growth was led by Diabetes Care, Structural Heart and Heart Failure and Electrophysiology. Several products, including FreeStyle Libre, Navitor, TriClip, and AVEIR, contributed to the strong performance. The Diabetes Care division reported organic sales growth of 19.6% year over year, led by sales of continuous glucose monitors, which accounted for $1.90 billion of total sales. Structural Heart sales rose 11.7%, and Heart Failure sales improved 14% year over year organically. The Vascular division recorded organic sales growth of 3.5%. The Electrophysiology, Rhythm Management and Neuromodulation divisions recorded organic growth of 10.3%, 9.8% and 4.3%, respectively, in the quarter under review. For the second quarter, Nutrition sales rose 2.9% year over year on a reported basis (up 3.4% organically) to $2.21 billion. Pediatric Nutrition sales were up 0.2%, and Adult Nutrition sales improved 6.6% organically. According to the company, Adult Nutrition sales benefited from the strong global growth of Ensure and Glucerna, Abbott's market-leading brands. For the second quarter, Diagnostics sales declined 1% year over year on a reported basis (down 1.4% organically) to $2.17 billion. Organic sales, ex-COVID, rose 0.8%. Core Laboratory Diagnostics sales were up 1.6% organically. Molecular Diagnostics' sales declined 3.4% on an organic basis. Rapid Diagnostics sales were down 6.8%. Point of Care Diagnostics sales decreased 5.2%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Margin Details of ABT In the second quarter, the gross profit rose 8.9% year over year to $6.29 billion despite a 5.4% increase in the cost of products sold (excluding amortization expense). The gross margin expanded 79 basis points (bps) to 56.4%. Selling, general and administration expenses rose 5.3% year over year to $3.09 billion. Research and development expenses rose 3.9% year over year to $725 million. The company reported an adjusted operating profit of $2.47 billion, up 15.5% year over year. Also, the adjusted operating margin expanded 156 bps to 22.2%. ABT's 2025 Financial Guidance Abbott expects full-year adjusted diluted EPS to be in the range of $5.10-$5.20 (earlier $5.05-$5.25). The Zacks Consensus Estimate for the metric is pegged at $5.16. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote Full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, is expected to be in the range of 7.5-8.0%, or 6.0-7.0% when including COVID-19 testing-related sales. The Zacks Consensus Estimate for sales is currently pegged at $44.70 billion, suggesting a 6.6% improvement from the 2024 level. For the third quarter of 2025, adjusted diluted EPS is expected to be between $1.28 and $1.32. The Zacks Consensus Estimate for the metric is pegged at $1.34. Our Take Abbott exited the second quarter of 2025 with better-than-expected results. Both its earnings and revenues beat their respective estimates. Additionally, the figures improved on a year-over-year basis. All business segments experienced growth during the reported quarter, except Diagnostics. Meanwhile, Abbott's Diagnostics sales growth continued to be adversely impacted by year-over-year declines in COVID-19 testing-related sales, along with volume-based procurement programs in China. During the reported quarter, Abbott announced favorable data from the AVEIR Conduction System Pacing (CSP) clinical feasibility study. Additionally, the company received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR) system — a first-of-its-kind device to help treat people with mitral valve disease. Meanwhile, Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia, expected to be completed by 2028. In addition, the expansion of both margins is encouraging. ABT's Zacks Rank and Other Key Picks Abbott currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Veeva Systems VEEV, Intuitive Surgical ISRG and Boston Scientific BSX. Veeva Systems, currently sporting a Zacks Rank #2, reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Boston Scientific, carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-07-2025
- Business
- Yahoo
Why Abbott Laboratories (ABT) Shares Are Plunging Today
What Happened? Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.1% in the afternoon session after the company reported second-quarter earnings that beat analyst expectations but maintained its full-year guidance, which may have disappointed investors hoping for a raised outlook. Abbott announced second-quarter adjusted earnings per share of $1.26 on revenue of $11.14 billion. These results surpassed Wall Street's consensus estimates, which called for an EPS of $1.25 and revenue of $11.07 billion. The company saw strong performance in its Medical Devices segment, which grew 13.4% on a reported basis, driven by robust sales in Diabetes Care, particularly its FreeStyle Libre products. Despite the solid quarterly performance, which included a 7.5% organic sales growth in its underlying base business, the company chose to maintain its full-year 2025 forecast. Abbott continues to project adjusted diluted EPS between $5.10 and $5.20. The decision not to raise guidance, even with the strong Q2 results, appears to be the primary driver behind the stock's negative reaction, as investors may have anticipated an upward revision. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Abbott Laboratories? Access our full analysis report here, it's free. What Is The Market Telling Us Abbott Laboratories's shares are not very volatile and have only had 1 move greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock gained 5.4% on the news that the company reported decent first-quarter 2025 results with revenue in line, although its organic revenue fell slightly short of Wall Street's estimates. EPS in the quarter beat slightly, while full-year EPS guidance met expectations. The full-year sales outlook was also maintained, which was encouraging despite the uncertain macro backdrop. Taking a closer look at the numbers, the company recorded a 12.6% organic growth in its Medical Devices segment, powered by robust demand for diabetes care and heart-related technologies. This strength helped lift total company organic sales by 6.9%, with double-digit growth in U.S. sales, even as Diagnostics weighed on results due to falling COVID-19 testing demand. Overall, this was a good quarter without many big surprises, which is a good thing in this market. Abbott Laboratories is up 6.2% since the beginning of the year, but at $120.48 per share, it is still trading 14.1% below its 52-week high of $140.22 from March 2025. Investors who bought $1,000 worth of Abbott Laboratories's shares 5 years ago would now be looking at an investment worth $1,214. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-07-2025
- Business
- Yahoo
Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors
Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year. The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion. Second-quarter sales increased 7.4% on a reported basis, 6.9% on an organic basis, or 7.5% when excluding COVID-19 testing-related U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management guidance of $1.23-$1.27. 'Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline,' said Robert B. Ford, chairman and chief executive officer, Abbott. 'We see this momentum carrying into 2026.' Medical Devices sales increased 13.4% on a reported basis and 12.2% on an organic basis to $5.37 billion. Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology. Several products contributed to the performance, including FreeStyle Libre, Navitor, TriClip, and AVEIR. In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4% on a reported basis and 19.6% organically. Worldwide Nutrition sales increased 2.9% (+3.4% on an organic basis) to $2.21 billion. View more earnings on ABT Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1% (+6.6% on an organic basis), led by strong growth of Ensure and Glucerna. Global Diagnostics sales decreased 1% (-1.4% on an organic basis) and increased 0.8% when excluding COVID-19 testing-related sales. The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China impacted diagnostics sales growth. COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million a year ago. Established Pharmaceuticals sales increased 6.9% (+7.7% on an organic basis) to $1.38 billion. Abbott's reported operating margin of 18.4%, with an adjusted operating margin of 22.9%, which reflects a 100 basis point increase. Guidance Abbott narrowed full-year 2025 adjusted earnings guidance from $5.05-$5.25 per share to $5.10-$5.20 per share compared to the consensus of $5.16. The company expects organic sales growth of 7.5%-8.0% compared to prior guidance of 7.5%-8.5%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%. Abbott expected third-quarter 2025 adjusted earnings of $1.28-$1.32 per share, compared to the consensus of $1.34 per share. During the earnings conference call, an Abbott executive addressed the impact of tariffs, reporting that the estimated headwind has been revised down to $200 million for the year, lower than previous estimates. Price Action: ABT stock is trading lower by 8.00% to $121.21 at last check Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ABBOTT LABORATORIES (ABT): Free Stock Analysis Report This article Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
